“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...

The primary objective of this report is to describe the safety of long-term use of EryDex in treatment of pediatric patients with ataxia telangiectasia. Methods: This is a post-hoc analysis of ...

Back to Healio Macular telangiectasia type 2 is a progressive and relatively rare neurodegenerative disease of the macula that typically affects patients who are older than 40 years of age ...

• In a large cohort of AT patients (n = 65), we observed reduced levels of B cells, CD4 + cells, and CD8 + T cells and no difference in the amount of NK and NKT cells in peripheral blood compared with ...